← GLW forward model

GLW · Forward model · Life Sciences and Emerging Growth Businesses · Springboard 2030 case

What has to happen in Life Sciences and Emerging Growth Businesses

Model as of

This page changes Life Sciences and Emerging Growth Businesses inside the complete GLW model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.

GLW forward model
Horizon
Consolidated fair value $165.54 all other verticals held in this portfolio case
Final-quarter revenue $270M 3% of company revenue
Explicit segment contribution −$20M EBITDA less segment capex, before corporate items

Management's own plan, taken literally. Corning states an annualised run rate of $20 billion by the end of 2026, $30 billion by the end of 2028 and $40 billion by the end of 2030, and a 19% sales CAGR from Q4 2026 to Q4 2030. On the run-rate definition Corning's own filings prove - Q4 core sales times four, since Springboard 'launched with an annualized sales run rate of $13 billion' against Q4 2023 core sales of $3,272m - that resolves to Q4 2030 core sales of $10,000m. The base case gets to $9,129m, so this case adds 0.75 points a quarter to Optical Communications alone, which is where the brief's arithmetic puts the burden: the other four segments cannot carry it. It reaches a $40.0 billion run rate. What it does NOT do is change the exit multiple or the discount rate - it is worth $165.54 a share, so even delivering the plan in full leaves the stock roughly 8% undervalued rather than transformed, because at 28x today's EBITDA a great deal of the plan is already in the price.

Life Sciences and Emerging Growth Businesses

Basis quarter$294M
Final quarter$270M
Implied CAGR−2%
Final revenue mix3%

The residual grouping left after the Q1 2026 restructure: laboratory consumables and pharmaceutical technologies plus other emerging businesses. Declining and loss-making - $294m of sales down 15% year over year and a $21m segment net loss, the only segment in outright decline. In the model it is a small drag, not a growth line.

Last four quarters
2025 Q3 $287M Reported
2025 Q4 $297M Reported
2026 Q1 $272M Reported
2026 Q2 $294M Reported
Life Sciences laboratory productsPharmaceutical TechnologiesOther emerging growth businesses
Sequential growth −1.5%/qtr decaying toward +0.2% Continued decline, but milder than the -3.9%/qtr implied by the year-over-year fall, which is measured against an outlier 2025 Q2.
Life Sciences and Emerging Growth Businesses

Latest: $270M (2030Q4E)

Period Value
2024Q1 $295M
2024Q2 $298M
2024Q3 $300M
2024Q4 $318M
2025Q1 $272M
2025Q2 $345M
2025Q3 $287M
2025Q4 $297M
2026Q1 $272M
2026Q2 $294M
2026Q3E $290M
2026Q4E $286M
2027Q1E $283M
2027Q2E $280M
2027Q3E $278M
2027Q4E $276M
2028Q1E $274M
2028Q2E $273M
2028Q3E $272M
2028Q4E $271M
2029Q1E $271M
2029Q2E $270M
2029Q3E $270M
2029Q4E $270M
2030Q1E $269M
2030Q2E $269M
2030Q3E $269M
2030Q4E $270M

Assumptions & reasoning

  • The -1.36% basis EBITDA margin is derived: net sales 294 less RD&E 27, depreciation 23 and other segment items 271 is -27 of segment pretax, plus 23 of depreciation back = -4. The segment lost money at the EBITDA line in the basis quarter.
  • The 8% terminal margin is a partial recovery toward the 9.86% this line earned in 2025 Q2. No management target exists for this segment, so it is an assumption and the single least evidenced number in the model - though on 3% of sales it moves fair value by cents.
  • Seasonality was measured and rejected: the whole 0.251 signal rests on one Q2 window of 1.139, and the following year contradicts it - if Q2 were genuinely 13% above trend, 2026 Q2 would not have come in 15% below the prior year.
  • Corning does not split Life Sciences from Emerging Growth Businesses inside this line, so the source of the decline is not attributable and no sub-split is attempted.
GLW model map

Explore another vertical